Odense, Denmark – Over the past two decades, immunotherapy – utilizing the body’s own immune system to combat illness – has emerged as a groundbreaking treatment for various types of cancer. The body’s own T-cells possess a remarkable capacity to identify and fight a wide range of cancers. Regrettably, cancer...
treatment News
MDUK is delighted to bring you the news that a highly complex, innovative gene therapy is to become available on the NHS in England for the treatment of spinal muscular atrophy (SMA) Type 1. Babies born with SMA Type 1, the most common form of the condition, are unable to...
NEW YORK, NY — Promontory Therapeutics Inc., a clinical stage pharmaceutical company advancing small molecule oncology approaches with immunotherapeutic effects, today announced that the pre-specified efficacy requirement of its Phase 2 study of PT-112 for recurrent thymoma has been exceeded. Patients with recurrent thymoma have limited options for standard of care treatment, and...
MELBOURNE, Australia — Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel treatments for chronic diseases such as recurrent and metastatic cancer, today announced that the Company and its joint research partners at the Universities of Jaén and Granada published key findings in a peer...
Garden City, NY — ProPhase Labs Inc. (NASDAQ: PRPH), a next-generation biotech, genomics, and diagnostics company, today reported its progress on the commercialization of its breakthrough BE-Smart test for esophageal cancer. The Company is aiming for commercial launch in the second half of 2024. Ted Karkus, CEO of ProPhase Labs,...
UNIONDALE, NY — ProPhase Labs, Inc. (NASDAQ: PRPH) today announced that its study, “Assessing Risk of Progression in Barrett’s Esophagus Using a Mass-Spectrometry-Based Proteomic Panel,” has been published online in Clinical and Translational Gastroenterology, the official journal of the American College of Gastroenterology (ACG). The publication presents full clinical validation data supporting BE-Smart,...
LEIDEN, Netherlands & CAMBRIDGE, Mass. – ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced results from a planned analysis of its Phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and...
WELLESLEY HILLS, Mass. — Joseph F. Finn, Jr., C.P.A. (“Finn”) announced today that Prospect Therapeutics has focused on developing GCS-100 for treatment of three blood-borne cancers: chronic lymphocytic leukemia (“CLL”), multiple myeloma (“MM”) and diffuse large B cell lymphoma (“DLBCL”). In clinical studies, GCS-100 has demonstrated activity as a single...
HERLEV, Denmark — A leading Danish cancer hospital has treated its first patient using RapidArc(R) radiotherapy after installing eight advanced radiotherapy treatment machines from Varian Medical Systems (NYSE: VAR) of Palo Alto, California. Herlev Hospital, to the north-west of Copenhagen, delivered the fast and efficient RapidArc treatment to a prostate...
A new prostate cancer risk assessment test, developed by a UCSF team, gives patients and their doctors a better way of gauging long-term risks and pinpointing high risk cases. According to UCSF study findings, published this week, the test proved accurate in predicting bone metastasis, prostate cancer-specific mortality, and all-cause...